The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.

about

The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.

Item

http://www.wikidata.org/entity/Q38510960

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The UZ Leuven Policy for Exten ...... ceptor-Positive Breast Cancer.

@en

type

Item

label

The UZ Leuven Policy for Exten ...... ceptor-Positive Breast Cancer.

@en

prefLabel

The UZ Leuven Policy for Exten ...... ceptor-Positive Breast Cancer.

@en

P1476

The UZ Leuven Policy for Exten ...... eceptor-Positive Breast Cancer

@en

P2093

An Poppe

http://www.w3.org/2001/XMLSchema#string

Anneleen Lintermans

http://www.w3.org/2001/XMLSchema#string

Hans Wildiers

http://www.w3.org/2001/XMLSchema#string

Kathleen Van Asten

http://www.w3.org/2001/XMLSchema#string

Kevin Punie

http://www.w3.org/2001/XMLSchema#string

Patrick Neven

http://www.w3.org/2001/XMLSchema#string

P2860

A gene-expression signature as a predictor of survival in breast cancer

Clinical application of the 70-gene profile: the MINDACT trial

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

P2888

s11864-015-0349-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-015-0349-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lynn Jongen

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023827044

http://www.w3.org/2001/XMLSchema#string

P698

26031545

http://www.w3.org/2001/XMLSchema#string

P921

estrogen-receptor positive breast cancer